Adjuvant chemotherapy improves overall survival in patients with stage IB non-small cell lung cancer

The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival and five-year OS in patients with tumor sizes ranging from 3-7 cm.